Drug Profile
Research programme: bile acid modulators - Albireo Pharma
Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Albireo Pharma
- Class Hepatoprotectants
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver disorders